Bristol-Myers Squibb
Bristol-Myers Squibb/ News/ News/ News/ Oncology/ R&D/ Top stories
BMS makes record $1.8bn bet on Nektar cancer drug
Richard Staines
Bristol-Myers Squibb, cancer, cancer immunotherapy, Merck & Co, Nektar Therapeutics, R&D
0 Comment
Bristol-Myers Squibb/ Cancer/ News
Clovis and BMS combine cancer drugs in late-stage trials
Richard Staines
BMS, cancer, Clovis, immunotherapy, Opdivo
0 Comment
Clovis and BMS research small molecule and antibody combination.
AstraZeneca/ Bristol-Myers Squibb/ Cancer/ News/ R&D/ UK & Europe
Soriot commits to AstraZeneca as shares slide
Andrew McConaghie
AstraZeneca, AZ, immuno-oncology, MYSTIC, Soriot
0 Comment
BMS appoints new science chief in fall-out from Opdivo setback
Richard Staines
Bristol-Myers Squibb, cancer, cancer immunotherapy, Merck & Co, R&D
0 Comment
Bristol-Myers Squibb/ Gilead/ News/ Novartis/ Pfizer
Is BMS the next pharma takeover target?
Richard Staines
Bristol-Myers Squibb, cancer, cancer immunotherapy, Gilead, M&A, Novartis, Pfizer
0 Comment
Speculation mounting that Pfizer and others could try for $90 bn plus merger
Bristol-Myers Squibb/ News/ R&D
Innate and BMS’ immunotherapy fails in phase 2 trial
Richard Staines
Bristol-Myers Squibb, cancer, cancer immunotherapy, Innate Pharma, R&D
0 Comment
French biotech developing cancer immunotherapy with BMS.
Bristol-Myers Squibb/ Merck Inc/ News/ R&D
BMS suffers further setback in lung cancer
Richard Staines
Bristol-Myers Squibb, cancer, cancer immunortherapy, lung cancer, Merck & Co, Oncology, R&D
0 Comment
No fast approval for immunotherapy combo in first line use.
Bristol-Myers Squibb/ News/ Novartis/ R&D/ UK & Europe/ US
Novartis, BMS, Janssen unveil R&D deals
Richard Staines
Biogen, Biotech, Bristol-Myers Squibb, cancer, cardiology, Ionis Pharmaceuticals, Janssen, Johnson & Johnson, JP Morgan healthcare conference, Novartis, US biotech
0 Comment
Companies announce eye-catching R&D plans ahead of conference.